Bristol-Myers Looks To A Promising Future

Pharmaceutical company

has some big opportunities on the horizon, and analysts are taking notice. At a time when many Pharma companies are beginning to worry about political battles over lowering drug prices, Bristol-Myers Squibb is hoping its bright future will outweigh any negativity coming from Washington as the company's cancer fighting drug Opdivo is

a major player in the cancer-treatment space throughout the coming years.

Opdivo is an immune-oncology drug that has been successful in blocking patients' T cell receptors and helping their immune systems detect cancerous cells and attack them. At the moment, Opdivo is the most successful immune-oncology drug on the market and has been approved for use against three different types of cancer. Opdivo was also the subject of Bristol-Myers' latest ad campaign as the firm looked to broaden patient interest in the drug.

Drugs that treat very specific illnesses or affect only a small segment of the population have become lucrative ways for drug companies to maintain their profits as more and more generic brands are created. At the moment, Bristol-Myers' Opdivo costs around $12,500 per month as there are no generic brands, making it a huge money maker for the company.

With such a promising future ahead, many are questioning why shares of BMY are down nearly 10 percent so far this year. The pharmaceutical industry has declined on a whole this year as the upcoming election has weighed on investor sentiment. Rising prescription drug prices have been a huge topic in this year's presidential campaigns, and many worry that the Pharma sector will suffer once a new administration takes over.